CollPlant Biotechnologies Ltd has demonstrated a remarkable revenue rebound in FY2025 powered by its proprietary plant-based recombinant human collagen (rhCollagen) technology. This bioidentical Type I collagen, produced via genetically engineered tobacco plants, forms the core of its regenerative medicine and aesthetics pipeline, including collaborations with AbbVie. Despite a 360% increase in revenue year-over-year, the company continues to operate at significant losses due to heavy R&D and operating expenses. Regulatory complexities and competitive pressures pose ongoing risks as CollPlant seeks to advance clinical milestones and broaden market penetration.